The "pay for delay" agreements involve one company paying other drugmakers to refrain from producing a generic version after the drug’s patent expires. The practices caused consumers "to pay as much as 90% more for drugs shielded from competition," state Attorney General Xavier Becerra's office said. Four settlements were reached with drug companies Teva Pharmaceutical Industries, Endo Pharmaceuticals and Teikoku Pharma. Meanwhile, Pfizer confirms its reported plans to absorb Mylan.
from Kaiser Health News https://ift.tt/2ZmKXnE
July 30, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Physicians Fear For Their Families As They Battle Coronavirus With Too Little ArmorDr. Jessica Kiss’ twin girls cry most mornings when she goes to work. They’re 9, old enough to know she could catch the coronavirus from her patients and get so sick she could die. Kiss shares that fear, and worries at least … Read More
Grocery Stores Install Plastic Shields In Checkout Lines To Protect Cashiers, CustomersA shopper at a Stop & Shop in Quincy, Massachusetts hailed the idea that's been cropping up across the country: “We’re supposed to be 6 feet away, but we’re closer to them. So that protection helps, and I feel safer.” New… Read More
Help Wanted: Retired Doctors And Nurses Don Scrubs Again In Coronavirus FightLaura Benson retired from nursing in 2018, but this week she reported for work again in New Rochelle, New York, where the first cluster of COVID-19 cases occurred a few short weeks ago. “Nurses are used to giving of themselve… Read More
In Coronavirus Relief Bill, Hospitals Poised To Get Massive Infusion Of CashCongress is on the verge of approving a massive funding bill that would steer an unprecedented amount of cash to the nation’s hospitals that are or soon will be struggling to cope with the COVID-19 pandemic. While the bottom-… Read More
First Edition: March 27, 2020Today's early morning highlights from the major news organizations. from Kaiser Health News https://ift.tt/3bve0Le … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment